You have 2 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lung Carcinomas, Non-Small-Cell

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Small Cell Lung Cancer, NSCLC, Lung Cancer Trial in Port Saint Lucie, Greenville (BL-B01D1)

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Port Saint Lucie, Florida
  • +1 more
Aug 11, 2023

EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine Trial run by the National Cancer Institute (NCI)

Recruiting
  • EGFR-Mutated Non-Small-Cell Lung Carcinoma
  • Small Cell/Neuroendocrine
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Metabolic Response to Food in Advanced Lung Cancer

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Weight loss (%)
  • (no location specified)
Jun 30, 2023

NSCLC With Mutation in Epidermal Growth Factor Receptor Trial (Osimertinib, Aspirin)

Not yet recruiting
  • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
  • (no location specified)
Aug 27, 2023

Non-Small-Cell Lung Cancer Trial in Guangzhou (PLB1004)

Recruiting
  • Non-Small-Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong General Hospital
Aug 25, 2023

NSCLC Trial in Guangzhou (PLB1001)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Aug 15, 2023

NSCLC, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation Trial in Fairfax (STX-721)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Fairfax, Virginia
    NEXT Virginia
Sep 18, 2023

T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy

Not yet recruiting
  • Non-small Cell Lung Cancer Metastatic
    • (no location specified)
    Sep 13, 2023

    NSCLC, NSCLC Trial in Guangzhou (Apatinib + Fluzoparib, Apatinib + Fluzoparib + Adebrelimab)

    Not yet recruiting
    • NSCLC
    • Non-small Cell Lung Cancer
    • Apatinib + Fluzoparib
    • Apatinib + Fluzoparib + Adebrelimab
    • Guangzhou, Guangdong, China
      Sun Yat-Sen University Cancer Center
    Jun 27, 2023

    NSCLC Trial in Iowa City (Durvalumab, Pharmacological ascorbate, Surgery (SOC))

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Iowa City, Iowa
      University of Iowa
    Oct 10, 2023

    Untreated Advanced NSCLC Trial in Fuzhou (Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and

    Recruiting
    • Untreated Advanced Non-small Cell Lung Cancer
    • Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy
    • Fuzhou, Fujian, China
      Fujian Cancer Hospital
    Nov 13, 2023

    NSCLC Trial (Furmonertinib)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • (no location specified)
    Aug 10, 2023

    NSCLC Trial in Rockville (Crizotinib - Usual, Crizotinib - Study)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Crizotinib - Usual
    • Crizotinib - Study
    • Rockville, Maryland
      Medicine Invention Design, Inc. - IORG0007849
    Aug 15, 2023

    ALK Positive NSCLC Trial in Guangzhou (Loratinib)

    Recruiting
    • ALK Positive Non-small Cell Lung Cancer
    • Guangzhou, Guangdong, China
      Guangdong Provincial Perople's Hospital
    Oct 19, 2023

    NSCLC Trial (Tislelizumab IV, Tislelizumab SC, Histology-Based Chemotherapy Doublet)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Tislelizumab IV
    • +2 more
    • (no location specified)
    Oct 25, 2023

    Advanced or Metastatic Squamous NSCLC Trial in Sydney (HMBD-001, Docetaxel, Cetuximab)

    Not yet recruiting
    • Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
    • Sydney, New South Wales, Australia
      GenesisCare North Shore
    Jun 20, 2023

    Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II, Nonsmall Cell Lung Cancer Stage III Trial in Tampa (Genomically

    Recruiting
    • Nonsmall Cell Lung Cancer
    • +3 more
    • Genomically Guided Radiation Therapy (RT)
    • Tampa, Florida
      Moffitt Cancer Center
    May 23, 2023

    Resectable Lung Non-Small Cell Carcinoma Trial in Atlanta (procedure, radiation, other)

    Not yet recruiting
    • Resectable Lung Non-Small Cell Carcinoma
    • Biospecimen Collection
    • +2 more
    • Atlanta, Georgia
      Emory University Hospital/Winship Cancer Institute
    Aug 22, 2023

    Cancer Medicines in Metastatic Non-small Cell Lung Cancer in

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • Oslo, Norway
      Pfizer Norway
    Apr 17, 2023

    NSCLC Trial (KB-GDT-01)

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
    • KB-GDT-01
    • (no location specified)
    Sep 29, 2023

    Lung Non-Small Cell Carcinoma Trial (Amivantamab, Biospecimen Collection, Computed Tomography)

    Not yet recruiting
    • Lung Non-Small Cell Carcinoma
    • Amivantamab
    • +3 more
    • (no location specified)
    Oct 30, 2023

    Carcinoma, Non-Small Cell Lung Trial in Zhengzhou (BAI combine with DEB-BACE)

    Not yet recruiting
    • Carcinoma, Non-Small Cell Lung
    • BAI combine with DEB-BACE
    • Zhengzhou, Henan, China
      Gang Wu
    Nov 7, 2023

    NSCLC?EGFR Sensitive Mutation Trial in Bengbu, Changsha, Shanghai (MCLA-129: 1500mg or 2000mg IV Q2W, Befotertinib: 75 mg or 100

    Not yet recruiting
    • Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
    • MCLA-129: 1500mg or 2000mg IV Q2W
    • Befotertinib: 75 mg or 100 mg Po QD
    • Bengbu, Anhui, China
    • +2 more
    Aug 28, 2023

    NSCLC, EGFR Sensitive Mutation, Adjuvant Therapy Trial in Beijing, Nanjing, Shanghai (Befotertinib + Icotinib , Icotinib +

    Recruiting
    • Non-Small Cell Lung Cancer
    • +2 more
    • Befotertinib + Icotinib placebo
    • Icotinib + Befotertinib placebo
    • Beijing, China
    • +2 more
    Sep 20, 2023

    NSCLC(NSCLC) Trial in Jinan (WX-0593 Tablets)

    Not yet recruiting
    • Non-Small Cell Lung Cancer(NSCLC)
    • WX-0593 Tablets
    • Jinan, Shandong, China
      Shandong Cancer Hospital and Institute
    Mar 1, 2023